KT-253
- Generic Name
- KT-253
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
KT-253 is a selective heterobifunctional small molecule degrader of mouse double minute 2 (MDM2).
- Associated Conditions
- -
- Associated Therapies
- -
Lirodegimod - Drug Targets, Indications, Patents
Kymera Therapeutics advances its immunology pipeline with KT-621 (STAT6) Phase 1 trial initiation, expecting data by mid-2025. Sanofi expands KT-474 (IRAK4) Phase 2 trials for HS and AD, aiming for completion by mid-2026. KT-295 (TYK2) selected for Phase 1 trials in 2025. Company shifts focus to immunology, with $911M cash extending runway to mid-2027.
Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights
Kymera Therapeutics reported $10.3M revenue, $745M cash balance, and a financial runway into 2027. Progressing KT-474 into Phase 2 trials, it faces competition and clinical trial risks. Encouraging data presented at medical meetings, with a focus on developing effective, safe oral treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath